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Background: The pathogenesis of inflammatory bowel disease (IBD) is complex, and an effective therapeutic
strategy has yet to be established. Recently, carbon monoxide (CO) has been reported to be capable of reducing
inflammation by multiple mechanisms. In this study, we evaluated the role of colonic CO insufflation in acute colitis
induced by trinitrobenzene sulfonic acid (TNBS) in rats.
Methods: Acute colitis was induced with TNBS in male Wistar rats. Following TNBS administration, the animals
were treated daily with 200 ppm of intrarectal CO gas. The distal colon was removed to evaluate various
parameters of inflammation, including thiobarbituric acid (TBA)-reactive substances, tissue-associated
myeloperoxidase (MPO) activity, and the expression of cytokine-induced neutrophil chemoattractant (CINC)-1 in
colonic mucosa 7 days after TNBS administration.
Results: The administration of TNBS induced ulceration with surrounding edematous swelling in the colon. In rats
treated with CO gas, the colonic ulcer area was smaller than that of air-treated rats 7 days after TNBS
administration. The wet colon weight was significantly increased in the TNBS-induced colitis group, which was
markedly abrogated by colonic insufflation with CO gas. The increase of MPO activity, TBA-reactive substances, and
CINC-1 expression in colonic mucosa were also significantly inhibited by colonic insufflation with CO gas.
Conclusions: Colonic insufflation with CO gas significantly ameliorated TNBS-induced colitis in rats. Clinical
application of CO gas to improve colonic inflammatory conditions such as IBD might be useful.
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Inflammatory bowel disease (IBD)Background
Inflammatory bowel disease (IBD) consists of chronic
and relapsing inflammatory diseases of the intestines;
the pathogenesis of IBD, including Crohn’s disease (CD)
and ulcerative colitis (UC), is complex. Although it has
been reported that genetic, immunologic, and environ-
mental factors are involved in the initiation and perpetu-
ation of chronic intestinal inflammation [1,2], the
precise pathogenesis remains unclear. 5-aminosalicylates
(5-ASA), corticosteroids, immunosuppressive agents, or* Correspondence: ynaito@koto.kpu-m.ac.jp
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reproduction in any medium, provided the oranti-tumor necrosis factor (TNF)-α antibodies are typic-
ally used for the management of IBD. However, a sub-
stantial number of patients of IBD experience relapse or
an incomplete response to these therapies.
The role of carbon monoxide (CO), a component of
cigarette smoke, has been reported [3] to provide protec-
tion against chronic intestinal inflammation. Although CO
is classified as a toxic agent that is potentially lethal and is
a major pollutant in industrialized society, CO has recently
emerged as a potent immunomodulatory entity, anti-
inflammatory agent, and an important factor in physio-
logical homeostasis [4-7]. The anti-inflammatory effect of
CO has been reported in various disease states and experi-
mental models, including ischemia-reperfusion injury [8,9],Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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saccharide (LPS)-induced sepsis [12]. In these conditions,
CO-mediated protection is associated with suppression
of the inflammatory cytokine response. We have previ-
ously reported that CO inhalation ameliorates 2,4,6-trini-
trobenzene sulfonic acid (TNBS)-induced murine colitis
through TNF-α expression in CD4+ T cells [13]. CO-
releasing molecule (CORM)-2 also suppressed colonic
inflammation induced by dextran sulfate sodium (DSS)
in mice [14]. In addition, CO inhalation suppressed in-
flammation in a genetically induced mouse colitis model,
in interleukin (IL)-10-deficient mice [15], and in T cell
receptor (TCR)α-deficient mice [16]. Based on these
reports, CO administration might represent a potential
therapeutic strategy for IBD.
In the present study, we demonstrated the beneficial
effect of CO in the colonic inflammatory condition by
using a TNBS-induced colitis model in rats with insuffla-
tion of CO gas into the colonic lumen.
Methods
Animals
Male Wistar rats weighing 180–200 g were obtained
from SHIMIZU Laboratory Supplies Co. Ltd. (Kyoto,
Japan). The animals were housed at 22°C in a controlled
environment with 12 h of artificial light per day; they
were allowed access to rat chow and water ad libitum.
The animals were maintained and all experimental pro-
cedures were carried out in accordance with the Na-
tional Institutes of Health (NIH) guidelines for the use
of experimental animals. All experimental protocols
were approved by the Animal Care Committee of the
Kyoto Prefectural University of Medicine (Kyoto, Japan).
TNBS-induced colitis in rats
Colitis was induced by the previously described method
[17]. In brief, the rats were anesthetized with pentobar-
bital sodium (Kyoritsu Seiyaku Corporation, Tokyo,
Japan). Following lower abdominal laparotomy, the
colon was exposed. The middle portion of the colon was
pinched with ring forceps (inside diameter, 8 mm), and
0.2 mL of 30% ethanol solution containing a final con-
centration of 0.2 M TNBS (Sigma-Aldrich Japan, Tokyo,
Japan) was injected into the luminal side of the clamped
portion of the colon. After 2 min, the colon was
returned to the abdominal cavity and the incision was
sutured. All procedures apart from TNBS injection were
performed in rats in the sham-operated control group.
Treatment protocol
Following TNBS administration, the animals were treated
daily with 200 ppm of CO gas. Colonic CO gas insufflation
(volume, 8 mL) was performed using a rubber catheter
(outer diameter, 2 mm) via the anus under light anesthesiawith diethyl ether (Wako Pure Chemicals, Osaka, Japan).
The colonic insufflation with CO gas performed twice a
day for 7 days after the induction of TNBS colitis in rats.
All animals were randomized into groups treated with co-
lonic CO gas insufflation or air insufflation.
The rats were sacrificed 7 days after TNBS treatment,
and the distal colon was removed and opened by longi-
tudinal incision. The wet colon weight was measured
immediately thereafter. The size of the ulcer was also
measured, and the ulcer index was calculated from the
resultant length and width measurements (mm2). For
histologic evaluation, formalin-fixed tissues were stained
with hematoxylin and eosin and evaluated by light
microscopy.Measurements of thiobarbituric acid (TBA)-reactive
substances and myeloperoxidase (MPO) activity
As an index of lipid peroxidation, the total concentration
of TBA-reactive substances was measured in the intes-
tinal mucosa as previously described [13,18]. Briefly, the
colonic mucosa was scraped off using 2 glass slides, and
was then homogenized with 1.5 mL of 10 mM potas-
sium phosphate buffer (pH 7.8) containing 30 mM KCl.
The level of TBA-reactive substances in the mucosal
homogenates was expressed as nmoles of malondialde-
hyde/mg of protein, using 1,1,3,3-tetramethoxypropane
as the standard. The total protein in the tissue homoge-
nates was measured with a Bio-Rad Protein Assay kit
(Bio-Rad Laboratories, K. K., Tokyo, Japan) according to
the manufacturer’s protocol.
Tissue-associated MPO activity in the intestinal mu-
cosa was determined as an index of neutrophil accumu-
lation as described elsewhere [13,18]. The mucosal
homogenates were centrifuged at 20,000 × g for 15 min
at 4°C to collect the insoluble cellular debris. The result-
ant pellet was then homogenized in an equivalent vol-
ume of 0.05 M potassium phosphate buffer (pH 5.4)
containing 0.5% hexadecyltrimethylammonium bromide.
The samples were centrifuged at 20,000 × g for 15 min at
4°C, and the supernatants were saved. MPO activity was
assessed by measuring the H2O2-dependent oxidation of
3,30,5,50-tetramethylbenzidine. One unit of enzyme activ-
ity was defined as the amount of MPO required to cause
a change in absorbance of 1.0/min at 645 nm and 25°C.Determination of the colonic mucosal content and mRNA
expression of cytokine-induced neutrophil
chemoattractant (CINC)-1
The concentration of rat CINC-1, a potent member of
the IL-8 family [19,20], in the colonic mucosal homoge-
nates was determined with the Rat GRO/CINC-1 Assay
kit (Immuno-Biological Laboratories Co., Ltd., Gunnma,
Japan), according to the manufacturer’s instructions.
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(and β-actin as the internal control), was determined
by real-time PCR according to the protocol used in
our previous study [13,14]. Tissue samples for mRNA
isolation were removed from colonic mucosa. Total
RNA was isolated by the acid guanidinium-phenol-
chloroform method with Isogen (Nippon Gene Co.
Ltd., Tokyo, Japan). The isolated RNA was stored at −70°C
until use in real-time PCR. For real-time PCR, 1 μg
of extracted RNA was reverse-transcribed into first-
strand complementary DNA (cDNA) using the High
Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA). Real-time PCR for
CINC-1 and β-actin performed with a 7300 Real-
Time PCR system (Applied Biosystems) using the
DNA-binding dye SYBRW Green for the detection of
PCR products. The primers had the following
sequences: CINC-1 sense, 50-CCATTAAGTGTCAACC
ACTGTGCTA-30; CINC-1 antisense, 50-CACATTTC
CTCACCCTAACACAAA-30; β-actin sense, 50-GAGC
AAACATCCCCCAAAGTT-30; and; β-actin antisense,
50-GCCGTGGATACTTGGAGTGACT-30. Relative quanti-
fication of gene expression from the real-time PCR data
was calculated relative to β-actin expression.Figure 1 Effects of CO insufflation into the colonic lumen on macrosc
trinitrobenzene sulfonic acid (TNBS)-induced injury. (A) Severe colitis w
necrosis, in TNBS-treated rats (normal air group). These changes were redu
(CO group). (B) The ulcer index was evaluated. *P< 0.01 compared to sham
receiving normal air insufflation. (C) The wet colon weight was measured. D
operated rats. #P< 0.05 relative to rats with TNBS-induced colitis receiving nStatistical analysis
The results are presented as the mean ± standard error
of the mean (SEM). Overall differences between the
groups were determined by one-way analysis of variance
(ANOVA). For cases in which the one-way ANOVA was
significant, differences between individual groups were
analyzed by Bonferroni’s multiple comparisons test. Dif-
ferences in which P < 0.05 were considered significant.
All analyses were performed using the GraphPad Prism
4 program (GraphPad Software Inc., San Diego, CA,
USA) for Macintosh.
Results
Effect of colonic insufflation with CO gas on
TNBS-induced colitis
After 7 days of treatment with TNBS, macroscopic find-
ings in the colon demonstrated severe colonic ulcer-
ation, with a marked difference in margin relative to the
normal mucosa in addition to surrounding edematous
swelling. In rats treated with colonic CO gas insufflation,
the area of the colonic ulcer was smaller than that of
air-treated rats (Figure 1A). More precisely, while the
ulcer index was 68.5 ± 3.7 mm2 in control rats, the ulcer
index in rats treated with colonically insufflated CO gasopic findings, mucosal damage score, and wet colon weight after
as induced, including hyperemia, edema, thickening, ulceration, and
ced in rats treated by CO insufflation into the colonic lumen
-operated rats. #P< 0.05 compared to rats with TNBS-induced colitis
ata represent the mean± SEM of 7 rats. *P< 0.05 relative to sham-
ormal air insufflation.
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colon weight was significantly increased in the TNBS
colitis group (air-treated rats). This increase was signifi-
cantly ameliorated by treatment with colonically insuf-
flated CO gas (Figure 1C).
The effects of treatment with the colonically insuf-
flated CO gas were also confirmed by histological exam-
ination. Figure 2 shows the representative histological
features of a normal colon in sham-operated rats (A),
those of TNBS-induced colitis group (treated with air, B)
and those of the CO gas-treated group (C). The admin-
istration of TNBS induced a marked thickening of the
colonic wall and large colonic ulceration with transmural
infiltration of numerous inflammatory cells (Figure 2B),
as compared to the normal colon (Figure 2A). However,
in rats treated with CO gas, an inhibition of both mural
wall thickening and colonic ulceration was observed
(Figure 2C).
Effect of colonic insufflation with CO gas on TBA-reactive
substances and MPO activity
The extent of lipid peroxidation was determined by
measuring the TBA-reactive substances present in the
colonic mucosa. In the sham-operated group, there were
no differences in the levels of intestinal TBA-reactive
substances between CO gas- and normal air-treated rats.
However, the TNBS-induced colitis caused a significant
increase in TBA-reactive substances compared to that of
the sham-operated rats. The increase in TBA-reactive
substances in the colonic mucosa was significantly inhib-
ited by colonic insufflation with CO gas (Figure 3A).
Neutrophil accumulation was also evaluated by the
measurement of tissue-associated MPO activity in co-
lonic mucosal homogenates. In the sham-operated ani-
mals, there were no differences in the MPO activities
between CO gas- and normal air-treated rats. In contrast,Figure 2 Effects of colonic insufflation with CO gas on histological fin
(TNBS)-induced injury. Histological appearance of colonic tissue in sham-
TNBS-induced colitis treated with colonic insufflation of CO gas (C). Histolo
thickening of the colonic wall and colonic ulceration, which was associated
wall thickening and colonic ulceration were reduced in rats treated with co
shown (40 ×magnification).MPO activity in the colonic mucosa was markedly
increased in animals with TNBS-induced colitis relative
to that of the sham-operated group. The MPO activity in
the colonic mucosa after the induction of colitis with
TNBS was significantly inhibited by treatment with co-
lonic CO gas insufflation (Figure 3B).
Effect of colonic insufflation with CO gas on CINC-1
protein and mRNA expression in the colonic mucosa
To further analyze the effects of the colonic insufflation
with CO gas on neutrophil accumulation in the colonic
mucosa, we assessed the colonic mucosal CINC-1 pro-
tein level using an enzyme-linked immunosorbent assay
(ELISA) and CINC-1 mRNA expression using real
time-PCR. The colonic CINC-1 protein level increased
significantly after the induction of colitis with TNBS.
The increase in CINC-1 in the colonic mucosa was sig-
nificantly inhibited by colonic insufflation with CO gas
(Figure 4A). RNA extracts obtained from the colon
were subjected to real-time PCR to measure CINC-1
gene expression. As shown in Figure 4B, subtle expres-
sion of the CINC-1 gene was revealed in sham-operated
rats, while CINC-1 transcription was enhanced in the
TNBS-treated rats. Treatment with CO gas suppressed
CINC-1 mRNA expression in the inflamed colonic tis-
sue (Figure 4B).
Discussion
In the present study, we demonstrated that insufflation
of CO gas into the colonic lumen decreased colonic mu-
cosal damage and inflammation induced by TNBS. To
our knowledge, this is the first report demonstrating the
anti-inflammatory effect of insufflation of CO gas into
the colonic lumen. The pathogenesis of IBD such as CD
and UC are complicated and remain unclear. Concur-
rently, although new treatment modalities such asdings in the colon 7 days after trinitrobenzene sulfonic acid
operated rats (A), rats with TNBS-induced colitis (B), and rats with
gical examination revealed that TNBS administration induced marked
with transmural infiltration of inflammatory cells. In contrast, both














































































Figure 3 Effects of CO insufflation into the colonic lumen on thiobarbituric acid (TBA)-reactive substances and tissue-associated
myeloperoxidase (MPO) activity. The level of TBA-reactive substances (A) and MPO activity (B) were significantly inhibited in rats treated with
CO gas insufflation. Data represent the mean± SEM of 7 rats. *P< 0.05 relative to sham-operated rats. #P< 0.05 relative to rats with TNBS-induced
colitis receiving normal air insufflation.
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been proposed for the treatment of IBD, the progress of
disease remains poorly controlled in some patients. We
suggest the possibility of the clinical application of CO
gas to control IBD.
Cigarette smoking has been reported to have a pro-
tective effect against the development of UC [21,22]. Al-
though the detailed mechanisms remain unclear, CO—a
component of cigarette smoke—has been reported to ab-
rogate colonic inflammation. The ability of CO to inhibit
colonic mucosal inflammation has been reported in an
experimental colitis model. IL-10-deficient (IL-10−/−)
mice develop chronic colitis, which is mediated by T-
helper (Th)-1 cytokines. CO exposure at a concentration
of 250 ppm for 7 days ameliorated colitis in IL-10−/−
mice [15]. In Th-1 mediated inflammation, CO
decreases the synergistic effect of interferon (IFN)- γ on
LPS-induced IL-12 p40 in murine macrophages. In
addition, CO exposure has been reported to alleviate
chronic colitis in TCRα−/− mice in which the disease is
























Figure 4 Effects of CO insufflation into the colonic lumen on CINC-1 e
(B) were significantly inhibited in rats treated with CO gas insufflation. Data
sham-operated rats. #P< 0.05 relative to rats with TNBS-induced colitis receconcentration of 250 ppm for 7 days decreased the col-
itis score and inflammatory cytokine expression in the
colonic mucosa. In that model, CO induced heme oxy-
genase (HO)-1 expression that was correlated with
increased IL-10 and IL-22 expression in macrophages,
suggesting that HO-1 induction by CO may be asso-
ciated with anti-inflammatory mechanisms. In our previ-
ous study, TNBS-induced murine colitis was also
improved by CO inhalation [13]. CO inhalation signifi-
cantly decreased the macroscopic colonic damage score,
amount of TBA-reactive substances, and MPO activity
in the colonic mucosa. Not only the expression of TNF-α
in the colonic mucosa, but also TNF-α production by
CD4+ T cells isolated from the spleen was significantly
inhibited by treatment with inhaled CO. Furthermore,
CORM-2 improved colonic mucosal inflammation and
damage in an experimental colitis model as well [14].
The disease activity index (DAI) score and MPO activity
in the colonic mucosa were significantly decreased by
treatment with CORM-2 in an acute mouse colitis
























xpression. The CINC-1 protein expression level (A) and mRNA level
represent the mean± SEM of 7 rats. *P< 0.01 relative to
iving normal air insufflation.
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tinocyte chemoattractant (KC) were decreased after
CORM-2 treatment.
In the present study, we administered CO into the co-
lonic lumen of rats, and CO insufflation significantly
improved the ulcer index and decreased wet colon
weight in a TNBS-induced colitis model. The level of
TBA-reactive substances and MPO activity were also
decreased after CO insufflation. The elevation of TBA-
reactive substances is a reliable indicator of lipid peroxi-
dation, which is closely associated with tissue damage
[23]. Since oxidative stress in the colonic mucosa is
closely related to neutrophil infiltration, the elevation of
TBA-reactive substances is suggested to be a subsequent
event of the elevation of MPO activity. These results in-
dicate that CO insufflation decreased neutrophil infiltra-
tion and subsequent mucosal damage. In addition, we
confirmed that the induction of CINC-1 in the colonic
mucosa by TNBS was significantly inhibited by CO
treatment. CINC-1 is a homolog of human IL-8 and
plays an important role in the acute phase of inflamma-
tion [24,25]. Although further study is necessary to elu-
cidate the detail mechanism by which CO suppresses
CINC-1 expression in the colonic mucosa, it is clear that
CO insufflation significantly reduced the expression of
inflammatory mediator CINC-1, which might result in
reduced mucosal inflammation.
More importantly, blood CO concentration was not
elevated after CO insufflation in the colonic lumen in
this study (data not shown), indicating that the rectal ad-
ministration of CO gas might be safety and realistic
route for clinical application though the inhalation of
CO gas caused the high toxicity through the high con-
centration of CO in blood. In addition, the unchanging
CO concentration in blood after the rectal administra-
tion of CO gas may indicate that CO act topically in co-
lonic mucosa. In previous study using murine colonic
epithelial cells, we demonstrated that CO inhibited the
production of keratinocyte chemoattractant (KC), which
has represented a closely related chemokine involved in
neutrophil recruitment [26] and been regarded as a
functional homologue of IL-8, through the inhibition of
NF-κB activation [14]. Similar to these results, Megias
et al. also described that CO inhibited IL-8 production
in a human colonic epithelial cell line, Caco-2, through
the inhibition of NF-κB activation [27]. In view of the
results from these recent investigations, the inhibition of
cytokine production might be an essential mechanism
by which CO yields anti-inflammatory effects.
For the management of IBD, since mucosal healing is
associated with a better outcome with decreased risk of
relapse and major surgery, direct assessment of severity
and mucosal healing using endoscopy is critical [28,29].
In particular, for combination therapy with infliximaband azathioprine in CD patients, endoscopy may help to
identify patients who will experience the best outcome
due to early intervention [30]. However, an association
between colonoscopy preparation and toxic megacolon
in severe UC has been suggested [31]. It has also been
reported that left-sided colonic mucosal ulcerations
might be induced by sodium phosphate preparation and
polyethyleneglycol [32,33]. Although the precise etiology
of this association is unknown, an increase in crypt cell
apoptosis has been suggested to be an important mech-
anism of mucosal damage due to colonoscopy prepar-
ation [34]. An association between colonoscopy and
exacerbation of UC symptoms has been also reported
[35]. As a constant air supply during the endoscopic
examination is indispensable for observing the colonic
mucosa, we suggest that CO insufflation used instead of
the normal air supply during endoscopic examination of
IBD patients might prevent colonic mucosal damage
induced by the preparation for colonoscopy.
Conclusions
In conclusion, we demonstrated the beneficial effect of
CO insufflation into the colonic lumen to decrease mu-
cosal inflammation. Although additional research is
required before CO gas can be used for clinical applica-
tions, it might be a useful new complementary thera-
peutic strategy for the management of IBD.
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